---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-25-000073"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:43:21.685864+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GoodRx Q1 2025 revenue in-line at $203M; raises FY adjusted EBITDA guidance

## Summary
- Revenue $203.0M, net income $11.1M (net income margin 5.4%).
- Adjusted EBITDA $69.8M (34.4% margin) beat guidance; FY adjusted EBITDA expectations raised.
- Adjusted Net Income $34.4M (16.9% margin).
- Maintains FY 2025 revenue guidance range.
- Over 7 million consumers of prescription-related offerings at quarter end.

## SEC filing metadata
- accession: 0001809519-25-000073
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951925000073/0001809519-25-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951925000073/gdrx-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-25-000073
- JSON: https://secwatch.observer/filing/0001809519-25-000073.json
- Plain text: https://secwatch.observer/filing/0001809519-25-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.